The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2021 | Tiragolumab and atezolizumab in metastatic esophageal cancer
Zev A. Wainberg, MD, Msc, UCLA School of Medicine, Los Angeles, CA, provides an overview of the Phase Ib trial (NCT02794571) of the anti-TIGIT antibody tiragolumab in combination with the anti-PD-L1 antibody atezolizumab in patients with refractory metastatic esophageal cancer. The current cohort of patients with esophageal cancer is a part of an expansion cohort in a trial assessing the preliminary safety and tolerability of tiragolumab and atezolizumab. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.
